HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

Autor: Cesare Sarrecchia, Alessandra Cappelli, Pasquale Aiello
Rok vydání: 2004
Předmět:
Male
HBsAg
hepatitis B surface antibody
Chronic lymphocytic leukemia
amlodipine
medicine.disease_cause
Antibodies
Monoclonal
Murine-Derived
antibody detection
Monoclonal
Medicine
Pharmacology (medical)
Chronic
hepatorenal syndrome
Leukemia
adult
disease course
article
virus diseases
Lamivudine
Antibodies
Monoclonal
Hepatitis B
Middle Aged
Infectious Diseases
candesartan
fludarabine
hepatitis B core antibody
hepatitis B surface antigen
lamivudine
rituximab
virus DNA
antigen detection
case report
chronic lymphatic leukemia
death
DNA determination
fatality
hepatitis B
Hepatitis B virus
human
hypertension
liver failure
male
virus reactivation
Antineoplastic Agents
Hepatitis B Antibodies
Hepatitis B Surface Antigens
Humans
Leukemia
B-Cell
Chronic
Virus Activation
Rituximab
medicine.drug
Microbiology (medical)
Settore MED/17 - Malattie Infettive
Antibodies
Antigen
Hepatitis
business.industry
B-Cell
medicine.disease
Virology
Leukemia
Lymphocytic
Chronic
B-Cell
digestive system diseases
Immunology
business
Zdroj: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 11(4)
ISSN: 1341-321X
Popis: A 51-year-old man who was hepatitis B surface antigen (HBsAg)-negative and positive for anti-hepatitis B surface antigen (anti-HBs) and anti-hepatitis B core antigen (anti-HBc), during rituximab therapy for chronic Lymphocytic leukemia, developed reactivation of hepatitis B virus (HBV) infection with hepatitis that proceeded towards hepatic failure and death in spite of lamivudine therapy. HBsAg remained persistently negative, notwithstanding a high HBV-DNA titer. Our observation, following other cases of fatal reactivation of HBV infection in patients receiving rituximab, suggests that, in all patients with previous markers of HBV infection, lamivudine prophylaxis should be considered during rituximab therapy.
Databáze: OpenAIRE
Externí odkaz: